Latest Egle Therapeutics News & Updates

See the latest news and media coverage for Egle. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
Egle Therapeutics (Egle)

Clinical-stage biotechnology company developing regulatory T cell-targeted medicines

egle-tx.com
Headquarters
Paris, France
Founded year
2020
Company type
Private company
Number of employees
50–52

Last updated

Latest news about Egle Therapeutics (Egle)

In short: Egle reported positive EGL-003 Phase 1 data and won €8 million in EU funding for an EGL-001 cancer trial.

Company announcements

Egle

Egle to present EGL-003 Phase 1 data at EADV

It shares safety and pharmacodynamic data from a completed Phase 1 single ascending dose study in healthy volunteers, supporting EGL-003's advancement to a multiple ascending dose trial in atopic dermatitis.

Egle

Egle presents preclinical data on EGL-003 at ESDR meeting

Dr. Jonathan Back, Autoimmunity Scientific Program Lead, highlights how the Phase 1 IL-2 Treg agonist mobilizes regulatory T cells to restore immune balance in inflamed tissue, including hidradenitis suppurativa.

Egle

Egle Therapeutics wins €8 million Horizon Europe grant

The EU funding supports an Egle-led consortium running a Phase 1/2 neoadjuvant trial of EGL-001 with pembrolizumab in head and neck squamous cell carcinoma.

Unlock all announcements with a

Media coverage

Le Point

Egle Therapeutics, at the forefront of immunotherapy, from the Curie Institute to clinics

Egle Therapeutics is a pioneer in the field of immunotherapy. This biotechnology company relies on research from the Curie Institute to fight cancer...

Unlock all articles with a

Never miss news about Egle

Track Egle and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.